Quotables
"Radio has no future."
Lord Kelvin, British mathematician and physicist ; 1897
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8057804 | Herpes simplex virus combined subunit vaccines and methods of use thereof This invention provides vaccines comprising two or more recombinant Herpes Simplex Virus (HSV) proteins selected from a gD protein, a gC protein and a gE protein; and methods of impeding immune evasion by HSV thereby vaccinating a subject against HSV and treating, s... | 11/15/2011 |
| 7935352 | Compositions and methods for vaccinating against HSV-2 This invention relates to a method for systemic immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a ... | 05/03/2011 |
| 7879339 | Compositions and methods for vaccinating against HSV-2 This invention relates to a method for systemic immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a ... | 02/01/2011 |
| 7811582 | Herpes viruses for immune modulation An attenuated herpes virus which lacks a functional vhs gene or a functional equivalent thereof, but which has a functional UL43 gene or functional equivalent thereof, stimulates an immune response when dendritic cells are infected with the virus. ... | 10/12/2010 |
| 7785605 | Herpes simplex virus mutant ICP0 protein A mutant virus of herpes simplex virus type 1 (HSV-1) can include a mutant protein involved in replication so as to impair or inhibit replication of HSV-1. The mutant HSV-1 can have a mutation in at least one phosphorylation site of a protein involved in replication... | 08/31/2010 |
| 7628993 | Compositions and methods for vaccinating against HSV-2 This invention relates to a method for systemic immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a ... | 12/08/2009 |
| 7407752 | Oligonucleotide complexes for use as anti-viral therapeutics The methods disclosed herein are of use for the treatment of a wide variety of diseases. In particular, the methods provide for the targeting of a transcription altering agent to a specific target site of a viral genome in order to inactivate the virus. In addition,... | 08/05/2008 |
| 7291488 | Detection of herpes simplex virus types 1 and 2 by nucleic acid amplification The present invention relates to a method of detecting the presence or absence of herpes simplex virus (HSV) in a sample based on amplifying a portion of the Glycoprotein G (US4) gene of HSV and detecting the presence of the amplified nucleic acid using primers and ... | 11/06/2007 |
| 7267940 | HSV-2 type-specific immunoassays using glycoprotein G2 peptides The present invention relates to peptides that are derived from HSV-2 glycoprotein G2 and represent HSV-2 type-specific epitopes. The present invention also provides for compositions comprising these peptides for type-specific serological diagnosis of HSV-2 infectio... | 09/11/2007 |
| 7264817 | Immunogenic composition based on a truncated derivative of a membrane bound protein and process for making it Disclosed is an invention related to the preparation and use of vaccines against pathogenic organisms, such as herpes virus. The vaccines hereof are based upon the use of truncated, membrane-free derivatives of a membrane-bound polypeptide from the pathogen. These p... | 09/04/2007 |
| 7223368 | Diffraction-based diagnostic devices A biosensor includes a substrate with a layer of receptive material disposed thereon. The receptive material is specific for an analyte of interest. A pattern of active and inactive areas of the receptive material are defined in the receptive material layer by a mas... | 05/29/2007 |
| 7220747 | Method for preventing damage to or rejuvenating a cellular blood component using mitochondrial enhancer This invention provides methods for treating cellular blood components and other cells containing mitochondria to improve vital qualities of the cells by contacting the cells with a mitochondrial enhancer to the cells. Mitochondrial enhancers prevent damage to and r... | 05/22/2007 |
| 7118755 | Herpes viruses for immune modulation An attenuated herpes virus which lacks a functional vhs gene or a functional equivalent thereof, but which has a functional UL43 gene or functional equivalent thereof, stimulates an immune response when dendritic cells are infected with the virus. ... | 10/10/2006 |
| 7094378 | Method and apparatus for inactivation of biological contaminants using photosensitizers Methods and apparatuses for treating fluids to inactivate microorganisms which may be present therein, said fluid containing one or more components selected from the group consisting of protein, blood and blood constituents are provided. The methods comprise adjusti... | 08/22/2006 |
| 7094767 | Polynucleotide herpes virus vaccine Genes encoding herpes simplex virus type 2 (HSV-2) proteins were cloned into eukaryotic expression vectors to express the encoded proteins in mammalian muscle cells in vivo. Animals were immunized by injection of these DNA constructs, termed polynucleotide vaccines ... | 08/22/2006 |
| 7070781 | Nontoxic mucosal adjuvant A non-toxic mucosal adjuvant is provided which may be admixed with further antigens to provide a vaccine administrable to mucosal surfaces in organisms including man. Preferably, the non-toxic mucosal adjuvant is a detoxified mutant of a bacterial ADP-ribosylating t... | 07/04/2006 |
| 7063851 | Herpes viruses for immune modulation A method of stimulating an immune response in a human or animal subject, which method comprises administering to a subject in need thereof an effective amount of an attenuated herpes virus which: (i) lacks a functional vhs gene, or... | 06/20/2006 |
| 7063835 | Virus strains The present invention relates to non-laboratory virus strains, for example of herpes viruses such as HSV, with improved oncolytic and/or gene delivery capabilities as compared to laboratory virus strains. ... | 06/20/2006 |
| 7064111 | Use of soluble costimulatory factor for tumor immuno-gene therapy A new gene therapy entails tumor treatment by introducing an expressible nucleotide sequence for a soluble costimulatory factor, thereby enhancing the response of T-cells to a tumor. In vivo expression of the soluble factor overcomes anergy or tolerance to tumor cel... | 06/20/2006 |
| 7064192 | High pressure refolding of protein aggregates and inclusion bodies The present disclosure provides an effective method for the refolding of denatured proteins in solution so that properly folded, biologically active protein in solution is recovered in high yield. The refolding takes place at pressures between about 0.25 kbar to abo... | 06/20/2006 |
| 7049110 | Inactivation of West Nile virus and malaria using photosensitizers Methods and apparatuses are provided for inactivation of microorganisms in fluids or on surfaces. Preferably the fluids contain blood or blood products and comprise biologically active proteins. Preferred methods include the steps of adding an effective, non-toxic a... | 05/23/2006 |
| 7037509 | Immunologically significant herpes simplex virus antigens and methods for using same The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are epitopes confirmed to be recognized by T-cells derived from herpetic lesions. T-cells having specificity for antigens of the invention have de... | 05/02/2006 |
| 7029678 | Vaccines The present invention provides vaccine compositions comprising an oil-in-water emulsion optionally with 3 De-O-acylated monophosphoryl lipid A and QS21. The vaccine compositions are potent induces of a range of immune responses. ... | 04/18/2006 |
| 6962709 | Immunologically significant herpes simplex virus antigens and methods for identifying and using same The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are epitopes confirmed to be recognized by T-cells derived from herpetic lesions. T-cells having specificity for antigens of the invention have de... | 11/08/2005 |
| 6946448 | In utero oral nucleic acid immunization Methods of nucleic acid immunization comprising the in utero delivery of nucleic acid molecules that encode one or more selected antigens to a vertebrate fetus are disclosed. ... | 09/20/2005 |
| 6936255 | Vaccine composition comprising herpes simplex virus and human papilloma virus antigens Novel combined vaccine compositions are provided, comprising a herpes simplex virus (HSV) antigen and a HPV antigen and optionally in addition one or more of the following: an EBV antigen, a hepatitis A antigen or inactivated attenuated virus, a hepatitis B viral an... | 08/30/2005 |
| 6932972 | Combined vaccine compositions Novel combined vaccine composition preferentially for administration to adolescents are provided, comprising a hepatitis B viral antigen and a herpes simplex viral antigen and optionally in addition one or more of the following: an EBV antigen, a hepatitis A antigen... | 08/23/2005 |
| 6863896 | Plant lectins as mucosal adjuvants The invention provides a method of increasing an immune response in a mammal. The method involves administering to the mammal an admixture comprising an immunogen and a plant lectin. The plant lectin acts as an adjuvant to increase an immune response against the imm... | 03/08/2005 |
| 6855317 | Immunological herpes simplex virus antigens and methods for use thereof The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are antigens and/or their constituent epitopes confirmed to be recognized by T-cells derived from herpetic lesions or from uterine cervix. T-cells... | 02/15/2005 |
| 6841373 | Herpes virus complementing cell line The present invention is directed to a cell line capable of supporting replication of a growth-defective Herpes Simplex Virus strain; specifically a replication-defective HSV-2 double mutant. Particularly disclosed is a cell line that expresses the ICP8 protein and ... | 01/11/2005 |
| 6821519 | Compositions and methods for the diagnosis and treatment of herpes simplex virus infection Compounds and methods for the diagnosis and treatment of HSV infection are provided. The compounds comprise polypeptides that contain at least one antigenic portion of an HSV polypeptide and DNA sequences encoding such polypeptides. Pharmaceutical compositions and v... | 11/23/2004 |
| 6814969 | Immunologically significant herpes simplex virus antigens and methods for using same The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are epitopes confirmed to be recognized by T-cells derived from herpetic lesions. T-cells having specificity for antigens of the invention have de... | 11/09/2004 |
| 6734167 | Uses of transport proteins This invention relates to uses of transport-active proteins, particularly of proteins and fusion polypeptides with the function of VP22, for control of the cell cycle, particularly in the reduction of the proliferating activity of proliferating cells. ... | 05/11/2004 |
| 6726910 | Immuno-reactive peptide CTL epitopes of human cytomegalovirus The invention provides a plurality of peptides (and immunologically functional variants thereof) which are immunogenic epitopes recognized by CD8+ class I MHC restricted cytotoxic T-lymphocytes of patients harboring latent human cytomegalovirus (HCMV) inf... | 04/27/2004 |
| 6723316 | Herpes simplex virus-1 Glycoprotein C mutants for treating unwanted hyperproliferative cell growth The present invention relates to pharmaceutical compositions, kits, and methods of use thereof, comprising, a mutant human herpes simplex virus, which is cytopathic to susceptible target cells, such as neoplastic cells. Preferably, the virus does not produce a funct... | 04/20/2004 |
| 6719982 | Mutant herpes simplex viruses and uses thereof The present invention provides a herpes simplex virus strain having a functional ICP27 gene and lacking at lease a functional ICP4 gene and a functional ICP34.5 gene. It also provides the use of a herpes simplex virus strain which lacks at least a functional ICP4 ge... | 04/13/2004 |
| 6713067 | Herpes viruses for immune modulation An attenuated herpes virus which lacks a functional vhs gene or a functional equivalent thereof, but which has a functional UL43 gene or functional equivalent thereof, stimulates an immune response when dendritic cells are infected with the virus. ... | 03/30/2004 |
| 6699481 | Peptides for inhibition of herpes simplex virus entry The invention includes antiherpesviral peptides and method of generating the same.... | 03/02/2004 |
| 6692752 | Methods of treating human females susceptible to HSV infection A method of administering a vaccine to females to prevent or treat infections associated with pathogens which cause sexually transmitted diseases is described. The vaccine comprises one or more antigens for the prevention or treatment of sexually transmit... | 02/17/2004 |
| 6673602 | Herpes simplex virus amplicon vector targeting system and method of using same The present invention relates to herpes simplex virus (HSV) amplicon vectors, and in particular, HSV-1 amplicon vectors, which have been genetically modified and used alone or with consequent genetically modified HSV virus, to target a selected cell type,... | 01/06/2004 |
